OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Pharmacokinetics and Pharmacodynamics is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Circadian rhythms: influence on physiology, pharmacology, and therapeutic interventions	43
Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during	34
Drug dosing during pregnancy—opportunities for physiologically based pharmacokinetic models	32
Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine	31
Enabling pregnant women and their physicians to make informed medication decisions using artificial intelligence	26
Two heads are better than one: current landscape of integrating QSP and machine learning	25
Fast screening of covariates in population models empowered by machine learning	25
Challenges in conducting clinical research studies in pregnant women	22
A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration	22
Recent applications of quantitative systems pharmacology and machine learning models across diseases	22
A kinetic proofreading model for bispecific protein degraders	21
Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2	20
Optimum multi-drug regime for compartment model of tumour: cell-cycle-specific dynamics in the presence of resistance	19
Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations	18
Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling	18
Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseases	16
Population pharmacokinetic model selection assisted by machine learning	16
Assessing parameter uncertainty in small-n pharmacometric analyses: value of the log-likelihood profiling-based sampling importance resampling (LLP-SIR) technique	15
Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome	15
Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1	15
Integration of physiological changes during the postpartum period into a PBPK framework and prediction of amoxicillin disposition before and shortly after delivery	14
Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits	14
Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies	13
Development of a genetic algorithm and NONMEM workbench for automating and improving population pharmacokinetic/pharmacodynamic model selection	12
Diffusion through skin in the light of a fractional derivative approach: progress and challenges	11

An integrative model of Parkinson’s disease treatment including levodopa pharmacokinetics, dopamine kinetics, basal ganglia neurotransmission and motor action throughout disease progression	11
Review of applications and challenges of quantitative systems pharmacology modeling and machine learning for heart failure	10
Two-pore physiologically based pharmacokinetic model validation using whole-body biodistribution of trastuzumab and different-size fragments in mice	9
Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women	9
Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system	8
Application of machine learning based methods in exposure–response analysis	8
Reduction of quantitative systems pharmacology models using artificial neural networks	8
Mathematical modeling of mammalian circadian clocks affecting drug and disease responses	7
A clinical population pharmacokinetic/pharmacodynamic model for BIIB059, a monoclonal antibody for the treatment of systemic and cutaneous lupus erythematosus	7
A physiological model of granulopoiesis to predict clinical drug induced neutropenia from in vitro bone marrow studies: with application to a cell cycle inhibitor	7
Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment	7
Well-tempered MCMC simulations for population pharmacokinetic models	7
What should patients do if they miss a dose of medication? A theoretical approach	6
Optimal control for colistin dosage selection	6
Wide size dispersion and use of body composition and maturation improves the reliability of allometric exponent estimates	6
Performance of longitudinal item response theory models in shortened or partial assessments	6
The rhythm of a preterm neonate’s life: ultradian oscillations of heart rate, body temperature and sleep cycles	6
Generative adversarial networks for construction of virtual populations of mechanistic models: simulations to study Omecamtiv Mecarbil action	6
Use of normalized prediction distribution errors for assessing population physiologically-based pharmacokinetic model adequacy	6
From data to QSP models: a pipeline for using Boolean networks for hypothesis inference and dynamic model building	5
A longitudinal item response model for Aberrant Behavior Checklist (ABC) data from children with autism	5
Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate	5
Physiologically-based pharmacokinetic model for 2,4-dinitrophenol	5
Population pharmacodynamic modeling of intramuscular and oral dexamethasone and betamethasone effects on six biomarkers with circadian complexities in Indian women	5
Development of PBPK model for intra-articular injection in human: methotrexate solution and rheumatoid arthritis case study	5
Towards a comprehensive assessment of QSP models: what would it take?	5
Prediction of CYP-mediated silybin A-losartan pharmacokinetic interactions using physiological based pharmacokinetic modeling	5
PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT	5
Application of Brunauer–Emmett–Teller (BET) theory and the Guggenheim–Anderson–de Boer (GAB) equation for concentration-dependent, non-saturable cell–cell interaction dose-responses	5
The Finite Absorption Time (FAT) concept en route to PBPK modeling and pharmacometrics	5
A novel approach for personalized response model: deep learning with individual dropout feature ranking	5
Machine learning-guided, big data-enabled, biomarker-based systems pharmacology: modeling the stochasticity of natural history and disease progression	5
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development	5
A pharmacokinetic and pharmacodynamic analysis of drug forgiveness	5
A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone	5
Exact solutions and equi-dosing regimen regions for multi-dose pharmacokinetics models with transit compartments	4
Delay differential equations based models in NONMEM	4
A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients	4
Development of minimal physiologically-based pharmacokinetic-pharmacodynamic models for characterizing cellular kinetics of CAR T cells following local deliveries in mice	4
Applications of cosinor rhythmometry in pharmacology	4
A semi-mechanistic exposure–response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases	4
Pharmacodynamic model of slow reversible binding and its applications in pharmacokinetic/pharmacodynamic modeling: review and tutorial	4
Estimating drug potency in the competitive target mediated drug disposition (TMDD) system when the endogenous ligand is included.	4
Modeling of levothyroxine in newborns and infants with congenital hypothyroidism: challenges and opportunities of a rare disease multi-center study	3
The influence of cardiac output on propofol and fentanyl pharmacokinetics and pharmacodynamics in patients undergoing abdominal aortic surgery	3
Pathway-level analysis of genome-wide circadian dynamics in diverse tissues in rat and mouse	3
A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosis	3
A quantitative systems pharmacology model of hyporesponsiveness to erythropoietin in rats	3
From complex data to biological insight: ‘DEKER’ feature selection and network inference	3
Two compartmental fractional derivative model with general fractional derivative	3

Training the next generation of pharmacometric modelers: a multisector perspective	3
Detection and impact of hysteresis when evaluating a drug’s QTc effect using concentration-QTc analysis	3
PBPK modeling of CYP3A and P-gp substrates to predict drug–drug interactions in patients undergoing Roux-en-Y gastric bypass surgery	3
Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney disease	3
Modeling the acute effects of exercise on glucose dynamics in healthy nondiabetic subjects	3
Knowledge dissemination and central indexing of resources in pharmacometrics: an ISOP education working group initiative	3
Experimental and computational assessment of the synergistic pharmacodynamic drug–drug interactions of a triple combination therapy in refractory HER2-positive breast cancer cells	3
A pharmacometrician’s role in enhancing medication use in pregnancy and lactation	3
A Bayesian population physiologically based pharmacokinetic absorption modeling approach to support generic drug development: application to bupropion hydrochloride oral dosage forms	3
COVID-19: opportunity arises from a world health crisis	3
Computing optimal drug dosing with OptiDose: implementation in NONMEM	2
Quantification of the endogenous growth hormone and prolactin lowering effects of a somatostatin-dopamine chimera using population PK/PD modeling	2
An integrated modelling approach for targeted degradation: insights on optimization, data requirements and PKPD predictions from semi- or fully-mechanistic models and exact steady state solutions	2
Semi-empirical anticoagulation model (SAM): INR monitoring during Warfarin therapy	2
Variability and uncertainty: interpretation and usage of pharmacometric simulations and intervals	2
A pharmacodynamic model of tidal volume and inspiratory sevoflurane concentration in children during spontaneous breathing	2
Evaluation of prompt engineering strategies for pharmacokinetic data analysis with the ChatGPT large language model	2
Statistical analysis of one-compartment pharmacokinetic models with drug adherence	2
Inferring pulmonary exposure based on clinical PK data: accuracy and precision of model-based deconvolution methods	2
Concentration–QTc analysis for single arm studies	2
Analysis of cellular kinetic models suggest that physiologically based model parameters may be inherently, practically unidentifiable	2
Should patients skip late doses of medication? A pharmacokinetic perspective	2
PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data	2
Exposure-response modeling improves selection of radiation and radiosensitizer combinations	2
A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis	2
R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Opisthorchis vive	2
Constant infusion case of one compartment pharmacokinetic model with simultaneous first-order and Michaelis–Menten elimination: analytical solution and drug exposure formula	2
Comparison of covariate selection methods with correlated covariates: prior information versus data information, or a mixture of both?	2
Clinical validation of translational antibody PBPK model using tissue distribution data generated with 89Zr-immuno-PET imaging	2
Population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling of bempedoic acid and low-density lipoprotein cholesterol in healthy subjects and patients with dyslipidemia	2
Application of different approaches to generate virtual patient populations for the quantitative systems pharmacology model of erythropoiesis	2
Estimation of time to progression and post progression survival using joint modeling of summary level OS and PFS data with an ordinary differential equation model	2
A latent variable approach to account for correlated inputs in global sensitivity analysis	2
Mechanistic inference of the metabolic rates underlying $$^{13}$$C breath test curves	1
Linking categorical models for prediction of pleasantness score using individual predictions of sweetness and creaminess: An advancement of categorical modeling	1
PKPD and cardiac single cell modeling of a DDI study with a CYP3A4 substrate and itraconazole to quantify the effects on QT interval duration	1
Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic urothelial carcinoma	1
A two-stages global sensitivity analysis by using the δ sensitivity index in presence of correlated inputs: application on a tumor growth inhibition model based on the dynamic energy budget theory	1
Individualized optimization of colistin loading doses	1
Improving priors for human monoclonal antibody linear pharmacokinetic parameters by using half-lives from non-human primates	1
A general model for cell death and biomarker release from injured tissues	1
Improved numerical stability for the bounded integer model	1
How circadian variability of the heart rate and plasma electrolytes concentration influence the cardiac electrophysiology – model-based case study	1
Understanding virtual patients efficiently and rigorously by combining machine learning with dynamical modelling	1
A longitudinal model for the Mayo Clinical Score and its sub-components in patients with ulcerative colitis	1
Do epoch lengths of hypnotic depth indicators affect estimated of blood-brain equilibration rate constants of propofol?	1
Pharmacometric model of agalsidase–migalastat interaction in human: a novel mechanistic model of drug-drug interaction between a therapeutic protein and a small molecule	1
Global sensitivity analysis in physiologically-based pharmacokinetic/pharmacodynamic models of inhaled and opioids anesthetics and its application to generate virtual populations	1
Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms	1
Target-mediated exposure enhancement: a previously unexplored limit of TMDD	1
Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)	1
The application of extreme value theory to pharmacometrics	1
Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach. 1. THR-149	1
A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy	1
A comparison of covariate selection techniques applied to pre-exposure prophylaxis (PrEP) drug concentration data in men and transgender women at risk for HIV	1
Mechanistic incorporation of FcRn binding in plasma and endosomes in a whole body PBPK model for large molecules	1
Generative models for age, race/ethnicity, and disease state dependence of physiological determinants of drug dosing	1
International society of Pharmacometrics Mentorship Program (IMP): feedback survey from the first cohort of mentor-mentee pairs	1
Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studies	1
Pharmacometric estimation methods for aggregate data, including data simulated from other pharmacometric models	1
Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition model	1
Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates	1
Generation and application of avatars in pharmacometric modelling	1
Current practices for QSP model assessment: an IQ consortium survey	1
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	1
Improving categorical endpoint longitudinal exposure–response modeling through the joint modeling with a related endpoint	1
A next generation mathematical model for the in vitro to clinical translation of T-cell engagers	1
A proof of concept reinforcement learning based tool for non parametric population pharmacokinetics workflow optimization	1
A quantitative systems pharmacological approach identified activation of JNK signaling pathway as a promising treatment strategy for refractory HER2 positive breast cancer	1
Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity	1
Accelerating robust plausible virtual patient cohort generation by substituting ODE simulations with parameter space mapping	1